ERBB2 and breast carcinoma: HER2 status variability in metastasis and heterogeneity within organs is known, with a report of potentially significant discordance in which the HER2 status in 44% of breast cancers shifted from HER2-negative to HER2-low; conversely, 22% exhibit the opposite trend [19].